Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Report Highlights

The global market for healthcare-acquired infection (HCAI) control should grow from $18.9 billion in 2018 to $24.7 billion by 2023 at a compound annual growth rate (CAGR) of 5.4% from 2018 through 2023.

Report Includes

• 42 data tables and 32 additional tables
• Industry analysis of the global healthcare-acquired infection (HCAI) control market
• Detailed overview and trend analysis of pharmaceutical treatment (antimicrobials and vaccines), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (catheters, patient ventilation devices, sterile intravenous [IV] filters) that prevent these infections
• Analyses of global market trends with data from 2017, estimates for 2018 and projections of compound annual growth rates (CAGRs) through 2023
• Emphasis on selected devices, pharmaceuticals and environmental products currently employed or under development for treatment of viral, bacterial and fungal infections
• Analysis of antimicrobial resistance and more specifically antibiotic resistance as a cause for these infections
• A look at the hospital surveillance methods and tools currently being used to prevent these infections
• Regional analysis of the market covering Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, Russia and Africa); and Asia-Pacific (i.e. Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries)
• Information on key patents and newer research developments in sterilization systems and devices
• Examination of vendor landscape and profiles of key players in the HCAI market, including Novartis, Pfizer, Roche, 3M Healthcare and Sanofi Pasteur

Report Scope

The report focuses on select drugs (antimicrobials), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (e.g. catheters, patient ventilation devices, sterile IV filters) that prevent occurrence of nosocomial infections.

Within each type of treatment, regional analyses will focus on the Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, Russia and Africa) and Asia-Pacific (i.e. Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries).

Analyst Credentials

Ms. Joshi has a Master's degree in Biotechnology from the Indian Institute of Technology (IIT), Mumbai, and a diploma in Management consulting from the Consultancy Development Centre, DSIR, Ministry of Science and Technology, India. She has about ten years of research experience in competitive intelligence, technology strategy and market analysis for companies in pharmaceuticals, biotechnology and agrochemical industry. Her recent reports for BCC Research include PHM180A Global Markets for Neglected Tropical Disease Treatments, published in June 2017, and PHM061D Global Markets for Infectious Diseases Treatments, published in March 2018.